QS Investors, LLC - AMPHASTAR PHARMACEUTICALS IN ownership

AMPHASTAR PHARMACEUTICALS IN's ticker is AMPH and the CUSIP is 03209R103. A total of 130 filers reported holding AMPHASTAR PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
QS Investors, LLC ownership history of AMPHASTAR PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2021$321,000
+9.9%
15,9000.0%0.00%
+33.3%
Q1 2021$292,000
-8.8%
15,9000.0%0.00%
-25.0%
Q4 2020$320,000
-17.9%
15,900
-23.6%
0.00%
-20.0%
Q3 2020$390,000
-74.8%
20,800
-69.8%
0.01%
-77.3%
Q2 2020$1,549,000
+50.4%
68,937
-0.6%
0.02%
+37.5%
Q1 2020$1,030,000
-25.3%
69,374
-2.6%
0.02%
+14.3%
Q4 2019$1,378,000
-4.1%
71,192
-1.7%
0.01%
-12.5%
Q3 2019$1,437,000
-6.1%
72,4470.0%0.02%
-5.9%
Q2 2019$1,530,000
+0.8%
72,447
-2.5%
0.02%0.0%
Q1 2019$1,518,000
+2.6%
74,2790.0%0.02%
-10.5%
Q4 2018$1,479,000
+3.5%
74,2790.0%0.02%
+35.7%
Q3 2018$1,429,000
+26.1%
74,2790.0%0.01%
+27.3%
Q2 2018$1,133,000
-18.7%
74,2790.0%0.01%
-21.4%
Q1 2018$1,393,000
-8.4%
74,279
-6.1%
0.01%0.0%
Q4 2017$1,521,000
+6.8%
79,064
-0.8%
0.01%
+16.7%
Q3 2017$1,424,000
-2.3%
79,683
-2.3%
0.01%0.0%
Q2 2017$1,457,000
+23.2%
81,5690.0%0.01%
+20.0%
Q1 2017$1,183,000
-21.3%
81,5690.0%0.01%
-16.7%
Q4 2016$1,503,000
+5.6%
81,569
+8.7%
0.01%
+9.1%
Q3 2016$1,423,000
+253.1%
75,026
+200.0%
0.01%
+266.7%
Q2 2016$403,00025,0070.00%
Other shareholders
AMPHASTAR PHARMACEUTICALS IN shareholders Q4 2020
NameSharesValueWeighting ↓
LAM GROUP, INC. 130,250$3,649,6053.75%
SHAKER INVESTMENTS LLC/OH 81,287$2,277,6621.41%
Mesirow Institutional Investment Management, Inc. 374,414$10,491,0801.38%
OBERWEIS ASSET MANAGEMENT INC/ 134,000$3,754,6800.80%
Portolan Capital Management 270,791$7,587,5640.75%
Hillsdale Investment Management Inc. 172,238$4,826,1090.41%
Capital Impact Advisors, LLC 14,669$411,0250.40%
Watershed Asset Management, L.L.C. 9,555$267,7310.34%
Quantedge Capital Pte Ltd 35,153$984,9870.33%
FEDERATED HERMES, INC. 3,284,217$92,023,7600.25%
View complete list of AMPHASTAR PHARMACEUTICALS IN shareholders